About Devbhoomi Pharmaceuticals Private Limited
Data last updated:
Devbhoomi Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 November 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74999DL2019PTC357104.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Rajan Dhawan and Sangeet Dixit.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at House No – 211/1 (F/F) Mashjid Moth, New Delhi, Delhi, India – 110049.
As per the financials filed for FY 2024, the company reported a revenue of ₹49,900, a growth of 55% compared to the previous year. For the same year it recorded a net profit of ₹2,070 (net margin 4.1%) and EBITDA of ₹3,000 (EBITDA margin 6%). Revenue has grown at a compounded annual rate (CAGR) of 18% over three years.
For more details, the company can be reached via its website devbhoomipharmaceuticals.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressHouse No – 211/1 (F/F) Mashjid Moth, New Delhi, Delhi, India – 110049
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Devbhoomi Pharmaceuticals Private Limited FY 2025 filings available
Devbhoomi Pharmaceuticals Private Limited reported revenue of ₹49,900 (up 55% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Devbhoomi Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 18% over three years, including 55% growth in the latest year. EBITDA fell 35% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Devbhoomi Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹3,000 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹2,070 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Devbhoomi Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 4.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Devbhoomi Pharmaceuticals are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nine Pharma Private Limited | ₹50,000 (FY 2021) | •••• | •••• | •••• | Aurangabad, Maharashtra, India | |
| Mortiyan-Byk Pharmaceuticals Private Limited | ₹50,000 (FY 2020) | •••• | •••• | 35.0% | •••• | Lucknow, Uttar Pradesh, India |
| Sattva Pharmaceuticals Private Limited | ₹50,000 (FY 2025) | •••• | •••• | -29.0% | •••• | Mumbai, Maharashtra, India |
| Norwes Pharmaceuticals Private Limited | ₹49,961 (FY 2017) | •••• | •••• | -97.0% | •••• | Uttar Pradesh, India |
| Astrozen Pharmaceuticals Private Limited | ₹49,914 (FY 2022) | •••• | •••• | 15.0% | •••• | Thane, Maharashtra, India |
| Devbhoomi Pharmaceuticals Private Limited this company | ₹49,900 (FY 2024) | •••• | •••• | 55.0% | •••• | New Delhi, Delhi, India |
| V. Jain Pharmaceuticals Private Limited | ₹49,802 (FY 2019) | •••• | •••• | -60.0% | •••• | Sikandrabad, Uttar Pradesh, India |
| Adven Lifecare Private Limited | ₹49,780 (FY 2025) | •••• | •••• | 36.0% | •••• | Gurugram, Haryana, India |
| Shakshansh Pharmaceuticals Private Limited | ₹49,643 (FY 2018) | •••• | •••• | •••• | Delhi, India | |
| Optimavibe Pharmaceuticals Private Limited | ₹49,100 (FY 2025) | •••• | •••• | •••• | Mirzapur Sadar, Uttar Pradesh, India | |
| Seasons Biologicals Private Limited | ₹49,010 (FY 2025) | •••• | •••• | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Devbhoomi Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals Private Limited is audited by SARS & ASSOCIATES for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SARS & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajan Dhawan Also directs: Nee See Healthcare Private Limited, Blubell Pharma Private Limited | Director | 06 Nov 2019 | 6 Years 11 Months | Current |
| Sangeet Dixit Also directs: Nee See Healthcare Private Limited, Blubell Pharma Private Limited | Director | 06 Nov 2019 | 6 Years 11 Months | Current |
Ownership and Shareholding of Devbhoomi Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Devbhoomi Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Devbhoomi Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals Private Limited has 2 board changes on record since 2019: 2 appointments. The latest: Rajan Dhawan was appointed as Director on 06 Nov 2019.
Credit Ratings, Litigation & Regulatory Alerts for Devbhoomi Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Devbhoomi Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Devbhoomi Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Devbhoomi Pharmaceuticals Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Devbhoomi Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Devbhoomi Pharmaceuticals Private Limited
Devbhoomi Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 November 2019 (7+ years old) and is registered under CIN U74999DL2019PTC357104.
Devbhoomi Pharmaceuticals reported revenue of ₹49,900 for FY 2024 (up 55% YoY).
Devbhoomi Pharmaceuticals has 2 current directors:
- Rajan Dhawan - Director
- Sangeet Dixit - Director
Devbhoomi Pharmaceuticals reported a net profit of ₹2,070 (net margin 4.1%) and EBITDA of ₹3,000 (EBITDA margin 6%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Devbhoomi Pharmaceuticals is 18% over three years. In the latest year (FY 2024) revenue rose 55%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Devbhoomi Pharmaceuticals is U74999DL2019PTC357104. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Devbhoomi Pharmaceuticals was incorporated on 06 November 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Devbhoomi Pharmaceuticals by revenue are Nine Pharma Private Limited, Mortiyan-Byk Pharmaceuticals Private Limited, Sattva Pharmaceuticals Private Limited, Norwes Pharmaceuticals Private Limited, Astrozen Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Rajan Dhawan was appointed as Director on 06 Nov 2019. Sangeet Dixit was appointed as Director on 06 Nov 2019.
Devbhoomi Pharmaceuticals can be reached through the website devbhoomipharmaceuticals.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Devbhoomi Pharmaceuticals is at House No – 2111 FF Mashjid Moth, New Delhi, Delhi, India – 110049.